NewsBenzingaGenentech 的 Giredestrant 联合 Everolimus 在 III 期 EvERA 研究中使 ITT 人群的疾病进展或死亡风险降低 44%,在 ESR1 突变的 ER 阳性晚期乳腺癌中降低 62%;FDA 的目标日期分别为晚期疾病 12 月 18 日和早期疾病 11 月 30 日 Genentech 的 Giredestrant 联合 Everolimus 在 III 期 EvERA 研究中使 ITT 人群的疾病进展或死亡风险降低 44%,在 ESR1 突变的 ER 阳性晚期乳腺癌中降低 62%;FDA 的目标日期分别为晚期疾病 12 月 18 日和早期疾病 11 月 30 日 Benzinga 2026.10.01 05:47 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Bitcoin Faces Historic Capitulation Levels: Can $62,000 Support Hold? $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg If You Invested $1000 In iShares Core S&P U.S. Growth ETF Stock 10 Years Ago, You Would Have This Much Today Kimball Electronics Says Co. Intends To Change Name To Kimball Solutions, Effective July 1, 2027; Expects To Change Ticker Symbol To KMBL
If You Invested $1000 In iShares Core S&P U.S. Growth ETF Stock 10 Years Ago, You Would Have This Much Today
Kimball Electronics Says Co. Intends To Change Name To Kimball Solutions, Effective July 1, 2027; Expects To Change Ticker Symbol To KMBL